Cargando…
A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx (®) in advanced breast cancer
PURPOSE: To compare the pharmacokinetic (PK) bioequivalence (BE) and safety of a generic pegylated liposomal doxorubicin (PLD) formulation with the reference product Caelyx(®). METHODS: A multicenter, single-dose, open-label, randomized, two-way crossover study was conducted in patients with breast...
Autores principales: | Li, Yinjuan, Qi, Lu, Wang, Yu, Li, Yan, Lei, Chunpu, Zhang, Yingjuan, Cheng, Xiaoqiang, Liu, Ju, Bai, HaiHong, Zhao, Xia, Lv, Shuzhen, Xiong, Bingjun, Liu, Juan, Shi, Yehui, Zhou, Huan, Li, Hongtao, Liu, Lihong, Jiang, Hongchuan, Ouyang, Weiwei, Li, Xiaowen, Li, Yanping, Wang, Xinghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810385/ https://www.ncbi.nlm.nih.gov/pubmed/36605440 http://dx.doi.org/10.3389/fonc.2022.1070001 |
Ejemplares similares
-
Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
por: Burade, Vinod, et al.
Publicado: (2017) -
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019) -
High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000) -
(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002) -
Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial
por: Li, Yinjuan, et al.
Publicado: (2020)